InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
8
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Schilke Tobin, Chief Financial Officer. Director active across 2 companies, notably Revance Therapeutics, Inc.. Aggregated, 33 filings have been published. Split: 0 buy · 8 sells. Total volume traded: €763k. History available since 30 June 2021. The latest transaction was disclosed on 20 August 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Schilke Tobin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations33 total
471 shares0Common StockSEC:0001628280-26-058664:0
6,713 shares@ US$39.67100.0% of flowCommon StockSEC:0001628280-26-014772:0
32,000 shares0Common StockSEC:0001628280-26-011728:0
52,000 shares0Common StockSEC:0000950170-25-037200:0
97,999 shares@ US$3.6526.6% of flowCommon StockSEC:0000950170-25-015362:0
6,888 shares0Common StockSEC:0000950170-25-014824:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-25-000005:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-24-000103:0
3,822 shares@ US$5.3051.4% of flowCommon StockSEC:0001479290-24-000066:0
17,447 shares0Common StockSEC:0001479290-24-000051:0
96,667 shares0Common StockSEC:0001479290-24-000015:0
434 shares@ US$7.470.2% of flowCommon StockSEC:0001479290-24-000005:0
22,620 shares0Common StockSEC:0001479290-23-000099:0
769 shares@ US$15.6060.8% of flowCommon StockSEC:0001479290-23-000083:0
2,701 shares@ US$30.575.9% of flowCommon StockSEC:0001479290-23-000077:0
42,349 shares0Common StockSEC:0001479290-23-000075:0
3,201 shares@ US$31.707.1% of flowCommon StockSEC:0001479290-23-000056:0
3,201 shares@ US$32.157.2% of flowCommon StockSEC:0001479290-23-000053:0
3,739 shares@ US$30.658.2% of flowCommon StockSEC:0001479290-23-000041:0
42,349 shares0Common StockSEC:0001479290-23-000036:0
3,201 shares@ US$33.507.8% of flowCommon StockSEC:0001479290-23-000031:0
2,085 shares@ US$33.215.0% of flowCommon StockSEC:0001479290-23-000018:0
3,201 shares@ US$34.607.8% of flowCommon StockSEC:0001479290-23-000015:0
1,000 shares@ US$31.002.2% of flowCommon StockSEC:0001479290-23-000012:0
1,701 shares@ US$25.003.1% of flowCommon StockSEC:0001479290-23-000007:0
25 of 33 declarations
About Schilke Tobin
Schilke Tobin is Directeur Financier at Revance Therapeutics, Inc. and Chief Financial Officer at Crinetics Pharmaceuticals, Inc. The 32 filings in the most recent sample run from 2021-07-02 to 2026-03-04, with EUR 763086 of sales and EUR 0 of purchases; the modal transaction nature is Attribution.
